Columbia Laboratories Inc.  

(Public, NASDAQ:CBRX)   Watch this stock  
Find more results for MHJP, Inc
0.00 (0.00%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.09 - 8.40
Open     -
Vol / Avg. 0.00/83,265.00
Mkt cap 64.54M
P/E 19.70
Div/yield     -
EPS 0.30
Shares 10.78M
Beta 0.90
Inst. own 24%
Apr 27, 2015
Q1 2015 Columbia Laboratories Inc Earnings Release (Estimated) Add to calendar
Mar 18, 2015
Q4 2014 Columbia Laboratories Inc Earnings Call
Mar 18, 2015
Q4 2014 Columbia Laboratories Inc Earnings Release
Mar 11, 2015
Columbia Laboratories Inc at ROTH Conference
Feb 9, 2015
Columbia Laboratories Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -13.08% 10.44%
Operating margin -1.49% 11.75%
EBITD margin - 18.22%
Return on average assets -6.83% 6.04%
Return on average equity -8.73% 7.66%
Employees 85 -
CDP Score - -


4Thna02floor, 4Na02libertyna02square
United States - Map
+1-973-4868820 (Phone)
+1-617-4820618 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Columbia Laboratories, Inc. (Columbia) is engaged in the development and analysis of pharmaceuticals, clinical trial manufacturing of pharmaceutical products for pharmaceutical company customers and the potential development of pharmaceuticals. The Company seeks to research and develop new therapeutic entities utilizing its drug delivery technology for licensing to pharmaceutical companies for commercialization. The Company is focused on the supply of CRINONE to its marketing partner and providing pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry through its wholly owned subsidiary, Molecular Profiles Limited. It has developed and brought to market five bioadhesive vaginal gel products, each commercialized through alliances. All the products developed by the Company utilize its Bioadhesive Delivery System (BDS), which consists of a polymer (polycarbophil) and an active ingredient.

Officers and directors

Stephen Garfield Kasnet Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Frank C. Condella Jr. President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
George O. Elston CPA Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Bridget A Martell Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Donald H. Hunter Director
Age: 58
Bio & Compensation  - Reuters
Nikin Patel Director
Age: 41
Bio & Compensation  - Reuters
Valerie L. Andrews Independent Director
Age: 55
Bio & Compensation  - Reuters
Frank Murdoch Armstrong Independent Director
Age: 57
Bio & Compensation  - Reuters
Cristina Csimma Pharm.D., M.H.P. Independent Director
Age: 55
Bio & Compensation  - Reuters